Clinical Trial

AB-3028, a Programmable Circuit T Cell Therapy in Patients With Castration Resistant Prostate Cancer (CRPC)

Recruiting Phase 1/2
View on ClinicalTrials.gov →
Summary
This is a multi-center, open-label Phase 1/2 trial evaluating the safety and efficacy of AB-3028 in subjects with metastatic castration resistant prostate cancer (mCRPC).
Protocol Amendment History 8 amendments
This ClinicalTrials.gov record has been amended 8 times since 2025-12-10; most recent amendment 2026-06-03.
Status change: Not Yet Recruiting → Recruiting 2026-01-09
Trial Details
NCT Number NCT07285694
Lead Sponsor Arsenal Biosciences, Inc.
Conditions Metastatic Castration Resistant Prostate Cancer (mCRPC)
Enrollment 190 participants
Start Date 2026-01-09
Primary Completion 2029-05 (estimated)
Study Completion 2031-05 (estimated)
Updated on ClinicalTrials.gov 2026-06-05